ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes

Mezencev, R.; Matyunina, L. V.; Wagner, G. T.; McDonald, J. F.*
Cancer Gene Therapy2016-12DOI: 10.1038/cgt.2016.71
34被引5阅读
引用收藏
分享

摘要

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal of malignancies, in large measure, due to the propensity of PDAC cells to acquire resistance to chemotherapeutic agents. A better understanding of the molecular basis of acquired resistance is a Major focus of contemporary PDAC research. We report here the results of a study to independently develop cisplatin resistance in two distinct parental PDAC cell lines, AsPC1 and BxPC3, and to subsequently examine the molecular mechanisms associated with the acquired resistance. Cisplatin resistance in both resistant cell lines was found to be multifactorial and to be associated with mechanisins related to drug transport, drug inactivation, DNA damage response, DNA repair and the modulation of apoptosis. Our results demonstrate that the two resistant cell lines employed alternative molecular strategies in acquiring resistance dictated, in part, by pre-existing molecular differences between the parental cell lines. Collectively, our findings, indicate that strategies to inhibit or reverse acquired resistance of PDAC cells to cisplatin, and perhaps other chemotherapeutic agents, may not be generalized but will require individual molecular profiling and analysis to be effective.

学科与关键词

关键词
APOPTOSIS PROTEINSSYSTEMS BIOLOGYMOLECULAR-BASISEXPRESSIONMECHANISMSADENOCARCINOMAOVEREXPRESSIONINHIBITORPHENOTYPECLUSTERIN
相关
加载中…
  • Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
    Lukas M., Braun; Simon, Lagies; Jessica, Guenzle; Stefan, Fichtner-Feigl; Uwe A., Wittel; Bernd, KammererCells, 2020, 9(5): 1251.
  • Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
    Liu, Kaidong; Geng, Yiding; Wang, Linzhu; Xu, Huanhuan; Zou, Min; Li, Yawei; Zhao, Zhangxiang; Chen, Tingting; Xu, Fengyan; Sun, Liang; Wu, Shuliang*; Gu, Yunyan*Molecular Oncology, 2022, 16(16): 3034-3051.被引 8
  • Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
    Li, Yunguang; Tang, Shijie; Shi, Xiaohan; Lv, Jingwen; Wu, Xueyuan; Zhang, Yehan; Wang, Huan; He, Juan; Zhu, Yiqin; Ju, Yi; Zhang, Yajuan; Guo, Shiwei; Yang, Weiwei*; Yin, Huiyong*; Chen, Luonan*; Gao, Dong*; Jin, Gang*CELL REPORTS MEDICINE, 2023, 4(9): 101162.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Gene Therapy
发表日期
2016-12
卷期
第 23 卷, 第 12 期
页码
446-453
DOI
10.1038/cgt.2016.71
语言
ENGLISH
成果收录
SCIE
资助标注
Petit Undergraduate Research Scholars Program of Parker H. Petit Institute for Bioengineering and Bioscience; Georgia Tech Foundation

作者

  • M

    Mezencev, R. (第一作者)

  • M

    Matyunina, L. V.

查看全部 4 位作者收起作者
  • W

    Wagner, G. T.

  • M

    McDonald, J. F. (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417